Giovanni Abbadessa

Also affiliated with Sanofi (France), Sanofi (United States), OPKO Health (United States), C3I (United States)

Biochemistry, Genetics and Molecular BiologyMedicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

1in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Papers

Driven by 2 papers. Top paper: “Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of SAR439459, a TGFβ inhibitor, as monotherapy and in combination with cemiplimab in patients with advanced solid tumors: Findings from a phase 1/1b study”.

Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of SAR439459, a TGFβ inhibitor, as monotherapy and in combination with cemiplimab in patients with advanced solid tumors: Findings from a phase 1/1b study

Clinical and Translational Science(2024)10.1111/cts.13854

N/A

0.360DataRank · unranked

10 citations

Debbie Robbrecht, Ryan Sullivan, Bernard Doger, Armando Santoro, Minal Barve +16 more

HER2-low expression in patients with advanced or metastatic solid tumors

Annals of Oncology(2023)10.1016/j.annonc.2023.08.005

N/A

0DataRank · unranked

72 citations

Cara Haymaker, Gabriela Raso, Serena Masciari, Lei Wang, Heather Lin +20 more